If you look at it positively, you could say: "Amy is great, she is trying to understand our disease and she will keep covering the story."
If you look at it negatively, you could say: "Amy is losing faith in the XMRV connection and she's covering more aspects of the disease, so that if the XMRV link gets disproven, it's not only XMRV articles she has to her name."
Whatever I think, I am very glad with this article and her continued investigations.
Whatever the reasons she has for broadening her focus, it can only be beneficial to us. If XMRV washes out, there will still be awareness of the other promising lines of research. If XMRV doesn't wash out, well, we still need the other lines of research to increase our understanding of the disease, not to mention the fact that some of the other research might bring us more benefits more quickly than XMRV. If XMRV is a go, it'll take quite a long time for treatment regimens to get tested adequately, verified, and approved.
And the thing we *really* fear - that if XMRV washes out we get tossed back in the "psychosomatic" wastebasket - is less likely to happen the more aggressively the other lines of research are pursued, and their findings widely publicized. I would like, I would really really like, to think that the re-wastebasketing can't happen at this point, when the information is so widely out there about the other physical abormalities being found in this disease.
It's my feeling that Amy's editors are giving her such free rein with this story because they are hoping to put her up for a Pulitzer. She already has one, after all. I do not doubt that she is a compassionate person who cares about the suffering of PWCs, (and her previous Pulitzer was for coverage of cancer issues, including its impact on patients, so she certainly has a feel for this type of subject), but I don't think the WSJ is giving so many column-inches to her coverage of ME/CFS out of kindness. Publishing such big stories is a business decision, and I don't think it's 100% motivated by the business implications of new ME/CFS tests and treatments coming on line, although that's certainly a part of it.